Metazol® Plus Suspension
Dual Action Antiamoebic & Anaerobicidal
  • Metazol® Plus : is a combination of Diloxanide  furoate; a luminal amoebicide and Metronidazole; a potent tissue amoebicide. They have a synergistic and comprehensive activity against all kinds of  amoebiasis either vegetative or cystic, and both intestinal or  extra-intestinal amoebiasis without need for addition drug.
  • Metronidazole is a 5-nitroimidazole derivative with activity against obligate anaerobic microorganism, both bacteria and protozoa. 
  • Metronidazole is widely distributed, it appears in most body tissues and fluids including bile, bone, breast milk, cerebral abscesses, CSF,  liver and liver  abscesses, saliva, seminal fluids and vaginal secretions and achieves concentration similar to those in plasma.
  • The mechanism of action of metronidazole is thought to involve  interference with DNA by a metabolite in which the nitro group of Metronidazole has been reduced. 
  • Because of rapid absorption of Metronidazole, it is probably less effective against parasites in the bowel lumen therefore it is used in conjunction  with a luminal amobicide diloxanide furoate in the treatment of invasive  amobiasis. 
  • Diloxanide furoate is a dichloroacetamide derivate, it is a luminal amobicide acting principally in bowel lumen.
  • Diloxanide furoate is suitable for eradication of the parasites in amoeba and giardia cyst passers. 

Each film coated tablet of Metazol® Plus contains :

  • Diloxanide furoate      250  mg
  • Metronidazole            200  mg

Each 5 ml of Metazol® Plus oral suspension contains :

  • Diloxanide  furoate    100  mg  
  • Metronidazole           200  mg (as Metronidazole benzoate)

Metazol® Plus is indicated in the treatment of :

  • Acute & chronic intestinal amoebic dysentery, amoebic hepatitis & amoebic liver abscess. 
  • Other systemic infections caused  by E. histolytica.
  • Giardiasis.
  • Eradication of amoeba and giardia cyst forms in cyst passer.
  • Hypersensitivity to any of the components of Metazol Plus.
  • Metronidazole increases blood levels of warfarin and other oral coumarin anticoagulants, resulting in prolongation of prothrombin time.         
  • Concomitant use of Alcohol with Metazol® Plus may lead to disulfiram like reaction.
  • Barbiturates and phenytoin increase the Metazol® Plus metabolism so  may diminish the antimicrobial effectiveness of Metronidazole (may be need to increase the dose). 
  • Metazol® Plus should be avoided during the first trimester of pregnancy. 
  • Metazol® Plus should be avoided during lactation, otherwise breast feeding should be stopped.
  • Flatulence and gastrointestinal disturbances especially: nausea,unpleasant metallic taste, vomiting , diarrhea  or constipation.    
  • Weakness, dizziness, ataxia, headache, drowsiness, skin rash.
  • In high doses or prolonged treatment with Metazol® Plus, peripheral  neuropathy and epileptic form seizures have been associated.
  • Metazol® Plus should be taken  with food, the patient should be advised to complete the course.    


  • 1 -2 Tablets : 3 times daily. 


  • Children over 12 years: one Tablet  3 times daily. 
  • Over 6years: ½ Tablet 3 time daily.


  • (2 – 5 years) : 2.5 – 5 ml 3 times daily.
  • (6 – 10 years): 10 ml 3 times daily.
  • (11 – 12 years): 15 ml 3 times daily.

* Duration of treatment is for 5 to 10 days and course of treatment may be repeated if necessary.

Metazol® Plus should be used with cautions in the following cases:

  • Doses should be reduced in elderly and in patients with severe liver or renal impairment.  
  • Patients with a history of blood dyscrasia, because the drug can cause leukopenia.        
  • Administration with caution in patients with CNS disease.               
  • If therapy with Metazol® Plus exceeds 10 days, regular clinical and  laboratory monitoring is advised. 

Metazol® Plus tablets:

  • Blisters of 10 Tablets, pack of 2 blisters.

Metazol® Plus oral suspension

  • Bottle of 100 ml. 
  • Store in a dry place at a temperature below 25°C.